aTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary Fibrosis

Core Insights - aTyr Pharma has advanced its investigational new drug candidate, ATYR0101, which will be presented at the ATS 2025 Respiratory Innovation Summit, highlighting its unique anti-fibrotic mechanism through interaction with LTBP-1 [2][4][5] Company Overview - aTyr Pharma is a clinical stage biotechnology company focused on developing first-in-class medicines from its proprietary tRNA synthetase platform [2][6] - The company’s lead therapeutic candidate is efzofitimod, which is in clinical development for interstitial lung disease [6] ATYR0101 Details - ATYR0101 is a fusion protein derived from the extracellular domain of aspartyl-tRNA synthetase (DARS) that induces apoptosis in myofibroblasts, which are crucial in the progression of fibrosis [3][5] - Preclinical data suggest that ATYR0101 may have the potential to reverse fibrosis, representing a significant advancement in treating pulmonary fibrosis [4][5] - The drug is currently undergoing IND-enabling studies, with an IND application anticipated to be filed in the second half of 2026 [4][5]